Catalyst Pharmaceuticals, which makes Firdapse, has applied for approval from the U.S. Food and Drug Administration under an orphan drug designation. That would give the company exclusive rights to market the drug for seven years.
That should be good news for LEMS patients. But the reality isn't so clear.
Read Full Article »